Automated Insulin Delivery: Progress and Future Needs

In recent years, significant strides have been made in the development of automated insulin delivery (AID) systems. These hybrid systems combine continuous glucose monitoring with insulin pumps to provide more precise and convenient blood sugar control.

Researchers have successfully translated these innovations from the laboratory to real-world use, improving the lives of people with type 1 diabetes.

As we look to the future, next-generation fully automated AID systems are being developed. These advancements could further reduce the burden of managing type 1 diabetes.

Potential approaches include using ultrarapid insulins, adjunctive therapies, and integration with additional wearables or dual-hormone systems.

Despite the progress made, there are still challenges to overcome. Comparing and selecting AID systems can be complex, and ensuring equitable access to these technologies is crucial for effective implementation.

Emerging evidence suggests that AID may also benefit other populations, including adults with type 2 diabetes, people with cystic fibrosis-related diabetes, and those in the inpatient setting.

Source: Diabetes care. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.